ImmuCell Corporation

NasdaqCM:ICCC Stock Report

Market Cap: US$75.6m

ImmuCell Management

Management criteria checks 2/4

ImmuCell's CEO is Paul F. Te Boekhorst, appointed in Nov 2025, has a tenure of less than a year. total yearly compensation is $675.93K, comprised of 10.2% salary and 89.8% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $81.41K. The average tenure of the management team and the board of directors is 4.4 years and 0.6 years respectively.

Key information

Paul F. Te Boekhorst

Chief executive officer

US$675.9k

Total compensation

CEO salary percentage10.24%
CEO tenureless than a year
CEO ownership0.1%
Management average tenure4.4yrs
Board average tenureless than a year

Recent management updates

Recent updates

Analysis Article • Dec 18

ImmuCell Corporation's (NASDAQ:ICCC) Price Is Right But Growth Is Lacking After Shares Rocket 34%

ImmuCell Corporation ( NASDAQ:ICCC ) shares have had a really impressive month, gaining 34% after a shaky period...
Analysis Article • Nov 15

These 4 Measures Indicate That ImmuCell (NASDAQ:ICCC) Is Using Debt Reasonably Well

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Analysis Article • Oct 18

Why Investors Shouldn't Be Surprised By ImmuCell Corporation's (NASDAQ:ICCC) Low P/S

With a price-to-sales (or "P/S") ratio of 1.9x ImmuCell Corporation ( NASDAQ:ICCC ) may be sending very bullish signals...
Analysis Article • Aug 22

ImmuCell (NASDAQ:ICCC) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Last week's profit announcement from ImmuCell Corporation ( NASDAQ:ICCC ) was underwhelming for investors, despite...
Analysis Article • May 22

We Think ImmuCell (NASDAQ:ICCC) Can Stay On Top Of Its Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Dec 04

ImmuCell Corporation (NASDAQ:ICCC) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

ImmuCell Corporation ( NASDAQ:ICCC ) shareholders would be excited to see that the share price has had a great month...
Analysis Article • Nov 30

ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Aug 07

Revenues Working Against ImmuCell Corporation's (NASDAQ:ICCC) Share Price

ImmuCell Corporation's ( NASDAQ:ICCC ) price-to-sales (or "P/S") ratio of 1.4x might make it look like a strong buy...
Analysis Article • Aug 10

ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • May 27

Insufficient Growth At ImmuCell Corporation (NASDAQ:ICCC) Hampers Share Price

You may think that with a price-to-sales (or "P/S") ratio of 2.6x ImmuCell Corporation ( NASDAQ:ICCC ) is definitely a...
Seeking Alpha • Aug 11

ImmuCell GAAP EPS of -$0.09, revenue of $3.86M

ImmuCell press release (NASDAQ:ICCC): Q2 GAAP EPS of -$0.09. Revenue of $3.86M (-15.0% Y/Y).
Seeking Alpha • Jul 07

ImmuCell announces preliminary 2Q sales of $3.9M

ImmuCell (NASDAQ:ICCC) announces preliminary sales results for Q2 of $3.9M, an decrease of 15% Y/Y. 1H sales of $9.9M, an increase of 14% Y/Y. “A material disruption in the supply to us of needed plastic parts limited our production and sales during the quarter. We had a backlog of orders worth approximately $704,000 as of June 30, 2022 that all could have been shipped to customers erasing this drop in sales for the quarter, if not for this supply disruption that we are working to resolve during the third quarter. The strategic investments we are making to incrementally expand our First Defense® manufacturing capacity further to approximately $30 million per year during the third quarter and to approximately $35 million per year during the fourth quarter are on track. Our work to achieve regulatory approval to commercialize Re-Tain® continues. We expect a response from the FDA during the third quarter to our submission of the final Technical Section required to complete our New Animal Drug Application, and we have submitted our responses to all of the findings from a recent pre-approval inspection by the FDA.” commented Michael F. Brigham, President and CEO.
Analysis Article • Sep 15

Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Jun 10

Why We Think Shareholders May Be Considering Bumping Up ImmuCell Corporation's (NASDAQ:ICCC) CEO Compensation

The impressive results at ImmuCell Corporation ( NASDAQ:ICCC ) recently will be great news for shareholders. This would...
Analysis Article • Mar 15

Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Analysis Article • Jan 22

Does ImmuCell's (NASDAQ:ICCC) Share Price Gain of 38% Match Its Business Performance?

Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...

CEO Compensation Analysis

How has Paul F. Te Boekhorst's remuneration changed compared to ImmuCell's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025US$676kUS$69k

-US$1m

Compensation vs Market: Paul F.'s total compensation ($USD675.93K) is about average for companies of similar size in the US market ($USD625.54K).

Compensation vs Earnings: Insufficient data to compare Paul F.'s compensation with company performance.

CEO

Paul F. Te Boekhorst (53 yo)

less than a year
Tenure
US$675,934
Compensation

Mr. Paul F. Olivier Te Boekhorst is President, CEO & Director of ImmuCell Corporation from November 1, 2025. Mr. Te Boekhorst served as Senior Vice President and General Manager of Water, Livestock, Poultr...

Leadership Team

NamePositionTenureCompensationOwnership
Paul F. Te Boekhorst
Presidentless than a yearUS$675.93k0.11%
$ 81.4k
Timothy Fiori
CFO, Secretary1.1yrsUS$430.28kno data
Bobbi Brockmann
Senior Vice President of Sales & Marketing11.3yrsUS$441.32k0.094%
$ 71.2k
Elizabeth Toothaker
Director of Finance & Administration and Controllerno datano datano data
A. Scaffa
Senior Director of Quality7.8yrsno datano data
John Zinckgraf
Director of Product Developmentno datano datano data
4.4yrs
Average Tenure
48yo
Average Age

Experienced Management: ICCC's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Paul F. Te Boekhorst
Presidentless than a yearUS$675.93k0.11%
$ 81.4k
Timothy Fiori
CFO, Secretaryless than a yearUS$430.28kno data
Gilles Guillemette
Independent Directorless than a yearno datano data
Paul Wainman
Independent Director12.2yrsUS$53.90k0.069%
$ 52.4k
David Tomsche
Independent Chair19.4yrsUS$63.90k1.45%
$ 1.1m
Kathy Turner
Independent Directorless than a yearno datano data
Gloria Basse
Independent Director5.9yrsUS$51.90k0.039%
$ 29.5k
Anthony DiMarco
Independent Directorless than a yearno datano data
0.6yrs
Average Tenure
61.5yo
Average Age

Experienced Board: ICCC's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/14 11:15
End of Day Share Price 2026/05/14 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ImmuCell Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan WeinsteinAegis Capital Corporation